Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical company Indevus Pharmaceuticals has completed enrollment in its second phase III trial for Sanctura XR, the company's once-daily formulation of Sanctura, which is currently marketed for overactive bladder.
Subscribe to our email newsletter
The company reported the completion of enrollment in the first of its two phase III trials earlier this month. Consistent with previous guidance, the company expects to file a new drug application with the FDA by the end of the calendar year.
The second of the two phase III trials has enrolled over 560 patients and the company anticipates reporting results in July of 2006. Both phase III trials are 12-week, double-blind, placebo-controlled studies, evaluating the effect of Sanctura XR in reducing frequency, urgency, and incontinence episodes in patients with overactive bladder.
Sanctura is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency. The most commonly reported side effects in phase III US clinical trials were dry and constipation.